ABNORMAL FIBRYNOLITIC ACTIVITY IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY

肥厚型心肌病患者纤维蛋白溶解活动异常

• 批准号: 4694695
• 负责人: M B LEON
• 金额: --
• 依托单位: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/4694695
• 关键词: disseminated intravascular coagulation; heart disorder diagnosis; human subject; hypertrophic myocardiopathy; longitudinal human study; myocardial ischemia /hypoxia; sudden cardiac death

Myocardial ischemia is an important associated event in patients with hypertrophic cardimyopathy which may be accompanied by abnormal intramyocardial coronary arateries, coronary vasodilator reserve abnormalities, and abnormal myocardial perfusion scans (using Thallium-201). To examine the hypothesis that thrombogenic factors may contribute to ischemia in patients with typertrophic cardiomyopathy. intrinsic fibrolytic activity was measured at rest and compared to a large normal population. We found that fibrinolytic activity was impared in most patients with hypertrophic cardiomyopathy and that abnormalities in fibrinolytic activity were not associated with frequency or severity of multiple paramenters of clinical disease. Long-term follow-up will be important to determine if these abnormalities in fibrinolytic activity are associated with a higher risk for intravascular trhombus formation which may result in ischemia, LV dysfunction, or sudden death.

心肌缺血是急性心肌梗死患者的重要相关事件 可能伴有异常的肥厚性心肌病 心肌内冠状动脉、冠状动脉血管扩张剂储备 异常和异常的心肌灌注扫描(使用 铊-201)。来检验血栓形成因子可能 会导致类型肥厚型心肌病患者的心肌缺血。 在静息状态下测量固有的纤溶活性，并与大容量的 正常人群。我们发现大多数患者的纤溶活性受到损害。 肥厚型心肌病患者和 纤溶活性与心绞痛的频率或严重程度无关 临床疾病的多个参数。长期的跟进将是 重要的是确定这些纤溶活性异常是否 与血管内滴虫形成的高风险相关， 可能导致缺血、左心功能不全或猝死。